Published in Cancer Epidemiol Biomarkers Prev on March 04, 2011
The known unknowns of HPV natural history. J Clin Invest (2011) 2.39
Updating the natural history of human papillomavirus and anogenital cancers. Vaccine (2012) 1.65
Prevalent serum antibody is not a marker of immune protection against acquisition of oncogenic HPV16 in men. Cancer Res (2011) 1.05
Seroprevalence of human papillomavirus (HPV) type 6 and 16 vary by anatomic site of HPV infection in men. Cancer Epidemiol Biomarkers Prev (2012) 0.95
Patterns of human papillomavirus DNA and antibody positivity in young males and females, suggesting a site-specific natural course of infection. PLoS One (2013) 0.95
Human papillomavirus infection: knowledge, attitudes, and behaviors among lesbian, gay men, and bisexual in Italy. PLoS One (2012) 0.90
Seroconversion Following Anal and Genital HPV Infection in Men: The HIM Study. Papillomavirus Res (2015) 0.89
Development of a generic microfluidic device for simultaneous detection of antibodies and nucleic acids in oral fluids. Biomed Res Int (2013) 0.88
HIV-1, HBV, HCV, HTLV, HPV-16/18, and Treponema pallidum infections in a sample of Brazilian men who have sex with men. PLoS One (2014) 0.88
Therapeutic Mechanisms of Treatment in Cervical and Vaginal Cancer. Oncol Hematol Rev (2012) 0.83
Association between rs2981582 polymorphism in the FGFR2 gene and the risk of breast cancer in Mexican women. Arch Med Res (2013) 0.82
HPV Prevalence in Multiple Anatomical Sites among Men Who Have Sex with Men in Peru. PLoS One (2015) 0.81
Role and uptake of human papillomavirus vaccine in adolescent health in the United States. Adolesc Health Med Ther (2011) 0.80
Oral HPV infection in a clinic-based sample of Hispanic men. BMC Oral Health (2014) 0.79
The prevalence of human papillomavirus infections and associated risk factors in men-who-have-sex-with-men in Cape Town, South Africa. BMC Infect Dis (2016) 0.78
Prostate-specific antigen is unlikely to be a suitable biomarker of semen exposure from recent unprotected receptive anal intercourse in men who have sex with men. Sex Transm Dis (2014) 0.77
HPV-QUEST: A highly customized system for automated HPV sequence analysis capable of processing Next Generation sequencing data set. Bioinformation (2012) 0.77
HPV Population Profiling in Healthy Men by Next-Generation Deep Sequencing Coupled with HPV-QUEST. Viruses (2016) 0.77
Cross-sectional study of HPV-16 infection in a population-based subsample of Hispanic adults. BMJ Open (2014) 0.76
Oral human papillomavirus infection in men might contribute to HPV serology. Eur J Clin Microbiol Infect Dis (2014) 0.76
Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran. Med Microbiol Immunol (2016) 0.76
Prevalence and risk factors for neutralizing antibodies to human papillomavirus types 16 and 18 in HIV-positive men who have sex with men. J Acquir Immune Defic Syndr (2013) 0.75
Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study. PLoS One (2016) 0.75
Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study. Cancer Res (2016) 0.75
Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med (1998) 11.61
Improved amplification of genital human papillomaviruses. J Clin Microbiol (2000) 11.50
Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev (2005) 9.47
Genotyping of 27 human papillomavirus types by using L1 consensus PCR products by a single-hybridization, reverse line blot detection method. J Clin Microbiol (1998) 9.43
Efficient intracellular assembly of papillomaviral vectors. J Virol (2004) 5.36
Oral sexual behaviors associated with prevalent oral human papillomavirus infection. J Infect Dis (2009) 5.24
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet (2011) 4.70
Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis (2006) 4.67
Effect of male circumcision on the prevalence of high-risk human papillomavirus in young men: results of a randomized controlled trial conducted in Orange Farm, South Africa. J Infect Dis (2009) 4.63
Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer (2004) 4.04
Genital human papillomavirus infection in men: incidence and risk factors in a cohort of university students. J Infect Dis (2007) 3.48
Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis (2002) 3.42
Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis (2000) 3.36
Human papillomaviruses. IARC Monogr Eval Carcinog Risks Hum (2007) 3.30
Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis (2004) 3.04
Male circumcision decreases acquisition and increases clearance of high-risk human papillomavirus in HIV-negative men: a randomized trial in Rakai, Uganda. J Infect Dis (2010) 2.70
Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis (2008) 2.56
Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis (2009) 2.43
Immune responses to human papillomavirus. Vaccine (2006) 2.37
Age-Specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis (2004) 2.21
The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis (1996) 2.21
Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis (2010) 2.10
Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer (2009) 2.01
Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis (2011) 1.84
Prevalence of and risk factors for anal human papillomavirus infection in men who have sex with women: a cross-national study. J Infect Dis (2010) 1.83
Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis (2009) 1.80
Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev (2004) 1.76
Risk factors for oral human papillomavirus in adults infected and not infected with human immunodeficiency virus. Sex Transm Dis (1997) 1.71
Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology (1994) 1.64
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis (2003) 1.57
Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica. Br J Cancer (2003) 1.55
Prevalence of and risk factors for anal human papillomavirus infection in heterosexual men. J Infect Dis (2008) 1.55
Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer (2008) 1.48
A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol (1997) 1.42
Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis (1998) 1.39
Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis (2004) 1.36
Test-retest reliability of a sexual behavior interview for men residing in Brazil, Mexico, and the United States: the HPV in Men (HIM) Study. Am J Epidemiol (2009) 1.33
Human papillomavirus DNA detection in male sexual partners of women with genital human papillomavirus infection. Urology (2005) 1.31
Seroepidemiology of infection with human papillomavirus 16, in men and women attending sexually transmitted disease clinics in the United States. J Infect Dis (2004) 1.17
Antibodies to human papillomavirus 16 and subsequent in situ or invasive cancer of the cervix. Cancer Epidemiol Biomarkers Prev (1997) 1.10
Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk women. J Infect Dis (1997) 1.08
Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients. Int J STD AIDS (2001) 1.07
Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men. Cancer Epidemiol Biomarkers Prev (2010) 1.03
HPV 6/11, 16, 18 seroprevalence in men in two US cities. Sex Transm Dis (2009) 1.02
Reduced clearance of penile human papillomavirus infection in uncircumcised men. J Infect Dis (2010) 1.01
Seropositivity against HPV 16 capsids: a better marker of past sexual behaviour than presence of HPV DNA. Genitourin Med (1997) 0.99
Seroprevalence of human papillomavirus types 6 and 16 capsid antibodies in homosexual men. J Infect Dis (1997) 0.98
HPV 16 antibody prevalence in Jamaica and the United States reflects differences in cervical cancer rates. Int J Cancer (1999) 0.98
Seroepidemiology of human papillomavirus type 11 in the United States: results from the third National Health And Nutrition Examination Survey, 1991--1994. Sex Transm Dis (2008) 0.87
Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med (2006) 9.93
Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol (2005) 9.67
A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med (2015) 7.99
Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 5.57
Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med (2009) 5.25
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis (2009) 5.09
Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med (2002) 4.75
Incidence and clearance of genital human papillomavirus infection in men (HIM): a cohort study. Lancet (2011) 4.70
HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med (2011) 4.69
Prevalence of HPV infection among men: A systematic review of the literature. J Infect Dis (2006) 4.67
Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ (2009) 4.31
Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine (2008) 4.31
Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst (2010) 4.20
Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol (2011) 3.98
The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev (2008) 3.93
The accuracy of noninvasive hemoglobin monitoring using the radical-7 pulse CO-Oximeter in children undergoing neurosurgery. Anesth Analg (2012) 3.71
The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis (2009) 3.55
Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. Int J Cancer (2006) 3.38
Incidence and clearance of oral human papillomavirus infection in men: the HIM cohort study. Lancet (2013) 3.25
Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell (2012) 3.21
Self-collection of vaginal specimens for human papillomavirus testing in cervical cancer prevention (MARCH): a community-based randomised controlled trial. Lancet (2011) 3.12
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res (2005) 3.08
Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res (2006) 3.00
Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev (2005) 2.86
Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine (2006) 2.78
Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res (2006) 2.68
Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine (2007) 2.64
Age-specific prevalence, incidence, and duration of human papillomavirus infections in a cohort of 290 US men. J Infect Dis (2008) 2.56
Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol (2002) 2.51
Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine (2006) 2.51
Multiparameter calibration of a natural history model of cervical cancer. Am J Epidemiol (2007) 2.49
An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (2008) 2.48
Missed clinical opportunities: provider recommendations for HPV vaccination for 11-12 year old girls are limited. Vaccine (2011) 2.43
A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila) (2009) 2.42
Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med (2002) 2.41
Human papillomavirus infections with multiple types and risk of cervical neoplasia. Cancer Epidemiol Biomarkers Prev (2006) 2.39
Chapter 24: Psychosocial aspects of vaccine acceptability. Vaccine (2006) 2.32
Physician referral for fertility preservation in oncology patients: a national study of practice behaviors. J Clin Oncol (2009) 2.31
Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin Cancer Res (2007) 2.28
Primary care utilization and colorectal cancer outcomes among Medicare beneficiaries. Arch Intern Med (2011) 2.21
Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis (2011) 2.19
Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer. Clin Cancer Res (2010) 2.19
Male circumcision and genital human papillomavirus: a systematic review and meta-analysis. Sex Transm Dis (2012) 2.16
Activation of stat3 in primary tumors from high-risk breast cancer patients is associated with elevated levels of activated SRC and survivin expression. Clin Cancer Res (2006) 2.11
The optimal anatomic sites for sampling heterosexual men for human papillomavirus (HPV) detection: the HPV detection in men study. J Infect Dis (2007) 2.11
Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis (2010) 2.10
Exertional desaturation as a predictor of rapid lung function decline in COPD. Respiration (2012) 2.09
HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine (2008) 2.09
Patterns of care and outcomes among elderly individuals with primary malignant astrocytoma. J Neurosurg (2008) 2.05
Circumcision and sexual behavior: factors independently associated with human papillomavirus detection among men in the HIM study. Int J Cancer (2009) 2.01
Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol (2008) 2.00
Serologic evidence for exposure to simian virus 40 in North American zoo workers. J Infect Dis (2004) 1.98
The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev (2010) 1.94
Incidence trends in primary malignant penile cancer. Urol Oncol (2007) 1.90
Condom use and other factors affecting penile human papillomavirus detection in men attending a sexually transmitted disease clinic. Sex Transm Dis (2004) 1.87
Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev (2007) 1.87
Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia. J Natl Cancer Inst (2003) 1.84
Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis (2011) 1.84
Prevalence of and risk factors for anal human papillomavirus infection in men who have sex with women: a cross-national study. J Infect Dis (2010) 1.83
Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study. J Infect Dis (2009) 1.80
Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer (2003) 1.78
The impact of a promotora on increasing routine chronic disease prevention among women aged 40 and older at the U.S.-Mexico border. Health Educ Behav (2004) 1.78
Sexual behavior, condom use, and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. Cancer Epidemiol Biomarkers Prev (2006) 1.77
Incidence, prevalence, and clearance of type-specific human papillomavirus infections: The Young Women's Health Study. J Infect Dis (2002) 1.77